 Well, look, so we've tested Imdeltra in patients with late-stage disease, and there it produces a three-times increase in survival out to about 14 months. What we want to do, Laura, is to continue to test this medicine in patients who have earlier-stage disease. We think there, if you can get into less advanced stages of small cell lung cancer, you may indeed, as you say, be able to get an even...